Prostate cancer in the elderly patient

Although malignant tumours occur at all ages, cancer disproportionately strikes individuals in the age group 65 years and older. The increasing statistical life expectancy of men together with the introduction of prostate specific antigen (PSA) as a screening tool have both contributed to a rising n...

Full description

Saved in:
Bibliographic Details
Published inAnnales d'urologie Vol. 40; no. 6; p. 336
Main Authors Waldert, M, Djavan, B
Format Journal Article
LanguageFrench
Published France 01.12.2006
Subjects
Age Factors
Aged
Biomarkers, Tumor - blood
Humans
Male
Mass Screening
Prognosis
Prostate-Specific Antigen - blood
Prostatectomy
Prostatic Neoplasms - blood
Prostatic Neoplasms - diagnosis
Prostatic Neoplasms - therapy
Treatment Outcome
Online AccessGet full text

Cover

More Information
Summary:Although malignant tumours occur at all ages, cancer disproportionately strikes individuals in the age group 65 years and older. The increasing statistical life expectancy of men together with the introduction of prostate specific antigen (PSA) as a screening tool have both contributed to a rising number of elderly men with a diagnosis of prostate cancer. Age is generally considered to be a key prognostic factor in terms of therapeutic decision making, perhaps as important as PSA level and Gleason score. Even in men over 70 years, treatment without curative intent may deprive frail patients of years of life. When considering local treatment, strong consideration should be given to radical surgery. Modern radical prostatectomy is associated with low perioperative morbidity, excellent clinical outcomes as well as long term disease control. Besides, overdiagnosis has led to the concept of expectant management for screening-detected small-volume, low grade disease, with intention of providing therapy for those men experiencing disease progression.
ISSN:0003-4401
DOI:10.1016/j.anuro.2006.09.002